Quest Diagnostics Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Quest Diagnostics Inc trades at $237.6 (market cap $26.21B), while Direxion Daily Semiconductor Bear 3X Shares trades at $40.26. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| DGX | SOXS | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $238.50 | $1.49K |
52-Week Low | $173.49 | $32.50 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $39.56, down 12.5% in the past 24 hours amid a bearish technical signal. The stock split 1:10 on July 15, 2026, and paid a $0.04 dividend in June 2026. Technical indicators show oversold conditions with an RSI of 26.30, while moving averages signal a downtrend.
The outlook remains highly speculative due to SOXS's inverse leverage structure, which amplifies losses in rising markets. Risks include semiconductor sector volatility and the ETF's decay from daily rebalancing. It suits only aggressive traders betting against chip stocks, not long-term investors.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →